In a groundbreaking clinical study published on May 21, 2025, in Nature, researchers from the Texas Biomedical Device Center (TxBDC) at The University of Texas at Dallas demonstrated unprecedented recovery rates in individuals with chronic, incomplete cervical spinal cord injuries using closed-loop vagus nerve stimulation (CLV).
The study involved 19 participants who underwent 12 weeks of therapy combining individualized rehabilitation with CLV. This approach delivered electrical pulses to the vagus nerve via a miniature implant activated during successful upper-limb movements, resulting in significant improvements in arm and hand function.
Notably, the therapy proved effective regardless of participants’ age, time since injury (ranging from 1 to 45 years), or initial impairment severity. Dr. Jane Wigginton, chief medical officer at TxBDC, highlighted that the therapy enabled patients to perform meaningful daily activities, such as fastening necklaces and zipping jackets, which were previously challenging. FOX 4 News Dallas-Fort Worth
This study serves as both a Phase 1 and Phase 2 clinical trial, with a randomized placebo-controlled design in its initial phase. The promising results have paved the way for a forthcoming Phase 3 pivotal trial involving 70 participants across multiple U.S. institutions specializing in spinal cord injury.
The CLV device, designed by Dr. Robert Rennaker, is approximately 50 times smaller than earlier versions and does not interfere with MRI, CT scans, or ultrasounds, marking a significant advancement in neurorehabilitation technology. FOX 4 News Dallas-Fort Worth
This innovative therapy builds upon over a decade of neuroscience and bioengineering research at UT Dallas, offering new hope for individuals with spinal cord injuries and potentially redefining rehabilitation approaches in neurology.
